FATE THERAPEUTICS INC Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Change in Unrealized Gain (Loss) (Deprecated 2019-01-31)
FATE THERAPEUTICS INC (FATE) reported Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Change in Unrealized Gain (Loss) (Deprecated 2019-01-31) of -$2.42 million for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-03.
Discontinued › Income Statement › Other Income
us-gaap:FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2016-03-03
- FATE THERAPEUTICS INC fair value, instruments classified in shareholders' equity measured on recurring basis, change in unrealized gain (loss) (deprecated 2019-01-31) for fiscal 2013 was -$2.42M.
| Period end | Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Change in Unrealized Gain (Loss) (Deprecated 2019-01-31) 12 month |
|---|---|
| 2013-12-31 | -$2.42M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |